CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

被引：5
|
作者：
Messori, Andrea [1 ]
Damuzzo, Vera [2 ]
Leonardi, Luca [3 ]
Agnoletto, Laura [3 ]
Chiumente, Marco [3 ]
Mengato, Daniele [3 ]
机构：
[1] Reg Hlth Serv, HTA Unit, Via San Salvi 12, I-50135 Florence, Italy
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Sch Hosp Pharm, Padua, Italy
[3] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 07期
关键词：
TIME;
D O I：
10.1016/j.clml.2020.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [41] Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
    Garcia-Sancho, Alejandro Martin
    Cabero, Almudena
    Gutierrez, Norma C.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [42] Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma
    Bojanini, Leyla
    Gupta, Neel
    Khaki, Ali Raza
    ONCOLOGIST, 2023, 28 (09): : 750 - 751
  • [43] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [44] Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
    Qu, Changju
    Zou, Rui
    Wang, Peng
    Zhu, Qian
    Kang, Liqing
    Ping, Nana
    Xia, Fan
    Liu, Hailing
    Kong, Danqing
    Yu, Lei
    Wu, Depei
    Jin, Zhengming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] COST ANALYSIS OF PATIENTS UNDERGOING ALLO HSCT OR CAR-T THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA FROM A GERMAN HEALTHCARE PAYER PERSPECTIVE
    Ahmadi, Paymon
    Ayuketang, Ayuk
    Ghandili, Susanne
    Konnopka, Claudia
    Morgner-Miehlke, Andrea
    Kroeger, Nicolaus
    Jakobs, Florian
    BONE MARROW TRANSPLANTATION, 2024, 59 : 748 - 748
  • [46] TREATMENT PREFERENCES AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Liu, F. F.
    Collacott, H.
    Clarke, H.
    Michaels-Igbokwe, C.
    VALUE IN HEALTH, 2023, 26 (06) : S316 - S316
  • [47] TREATMENT PATTERNS AND COST ANALYSIS AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Nabhan, C.
    Myerscough, C.
    Kish, J.
    Chung, J.
    Chopra, D.
    VALUE IN HEALTH, 2019, 22 : S82 - S82
  • [48] A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
    Cho, Jeong-Yeon
    Jang, Suk-Chan
    Kang, Dong-Won
    Lee, Eui-Kyung
    Koh, Hyein
    Yoon, Dok Hyun
    Park, Mi-Hai
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
    Frontzek, Fabian
    Karsten, Imke
    Schmitz, Norbert
    Lenz, Georg
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [50] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Vacirca, Jeffrey
    Tabbara, Imad
    Acs, Peter
    Shumaker, Grace
    BLOOD, 2010, 116 (21) : 1157 - 1157
12345